Herpes simplex virus encephalitis with progressive severe white-matter lesions

Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis

Herpes simplex virus 1 (HSV-1) can be responsible for life-threatening HSV encephalitis (HSE). The mortality rate of patients with HSE who do not receive antiviral treatment is 70%, with most survivors suffering from permanent neurological sequelae. The use of intravenous acyclovir together with improved diagnostic technologies such as PCR and magnetic resonance imaging has resulted in a reduction in the mortality rate to close to 20%. However, 70% of surviving patients still do not recover complete neurological functions. Thus, there is an urgent need to develop more effective treatments for a better clinical outcome. It is well recognized that cerebral damage resulting from HSE is caused by viral replication together with an overzealous inflammatory response. Both of these processes constitute potential targets for the development of innovative therapies against HSE. In this review, we discuss recent progress in therapy that may be used to ameliorate the outcome of patients with HSE, with a particular emphasis on immunomodulatory agents. Ideally, the administration of adjunctive immunomodulatory drugs should be initiated during the rise of the inflammatory response, and its duration should be limited in time to reduce undesired effects. This critical time frame should be optimized by the identification of reliable biomarkers of inflammation.

Diffusion-weighted imaging and apparent diffusion coefficient evaluation of herpes simplex encephalitis and Japanese encephalitis

PURPOSE

The aim of the study was to evaluate (a) the role of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) values in differentiating necrotising herpes simplex encephalitis (HSE) and non-necrotising Japanese encephalitis (JE) and (b) to correlate the ADC values with the duration of illness.

MATERIALS AND METHODS

Forty-five confirmed cases of encephalitis (38 patients with JE and 7 patients with HSE) underwent MR imaging. IgM antibody capture enzyme-linked immunosorbent assay (IgM MAC-ELISA) and polymerase chain reaction (PCR) tests were performed in cerebral spinal fluid (CSF) sample to confirm the diagnosis of JE and HSE respectively. MRI findings were recorded in terms of site of involvement, extent of lesions, visibility of each lesion on T2W, DWI and FLAIR sequences and ADC calculations. To observe the changes in ADC with duration of illness, patients with JE and HSE were regrouped on the basis of time since clinical presentation. Mean of the ADC value in each patient was noted and subjected for statistical analysis.

RESULTS

In HSE lesions there was a significant restricted diffusion with low average ADC values observed in acute stage and facilitated diffusion with high average ADC values observed in chronic stage. Whereas JE lesions did not show restricted diffusion and significant low ADC values in acute stage, though facilitated diffusion and high ADC values were observed in chronic stage.

CONCLUSION

The diffusion abnormality and conspicuity of lesions on DWI may be different in various acute encephalitis (HSE and JE). The ADC values are different in the acute stages of HSE and JE reflecting the difference in the degree of diffusability of water molecule. These observations may suggest that there may be an abundance of cytotoxic oedema in HSE and paucity of cytotoxic oedema in JE, in acute stage.

The spectrum of herpes simplex encephalitis in children

Clinical and basic science research carried out in recent years into herpes simplex encephalitis (HSE) have shown that the concept of a "classical" picture of HSE in children is now outdated and that our current knowledge of the disease is probably only the tip of an iceberg. Indeed, increasing evidence supports the existence of a wider range of pathophysiological mechanisms, clinical presentations and disease progressions in paediatric HSE. This paper reviews the clinical, biological and radiological data available and redefines the spectrum of HSE in children. Full understanding of the condition should improve the management of suspected cases and decrease the morbidity and the mortality associated with this disease.